Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial
Authors:
- Ricardo Ladeiras-LopesRLRicardo Ladeiras-Lopes
- Francisco SampaioFSFrancisco Sampaio
- Sara LeiteSLSara Leite
- Diogo Santos-FerreiraDSDiogo Santos-Ferreira
- Eduardo VilelaEVEduardo Vilela
- Adelino Leite-MoreiraALAdelino Leite-Moreira
- Nuno BettencourtNBNuno Bettencourt
- Vasco GamaVGVasco Gama
- Pedro BragaPBPedro Braga
- Ricardo Fontes-CarvalhoRFRicardo Fontes-Carvalho
- 8 April 2021
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 72 (3) , 699-710
Abstract
Purpose Metabolic syndrome (MetS) affects one out of 3 adults in the western world and is associated with preclinical diastolic dysfunction that impairs functional capacity and quality of life (QoL). This randomized trial was designed to evaluate if the addition of metformin to the standard treatment of non-diabetic patients with MetS improves diastolic dysfunction. Methods Prospective, randomized, open-label, blinded-endpoint trial. Fifty-four non-diabetic adults with MetS and diastolic dysfunction were randomized to lifestyle counseling or lifestyle counseling plus metformin (target dose 1000 mg bid). The primary endpoint was the change in mean e’ velocity (assessed at baseline, 6, 12 and 24 months). Secondary endpoints were improvements in insulin resistance, functional capacity and QoL. Linear mixed effects modeling was used for longitudinal data analysis using modified intention-to-treat (mITT) and per-protocol (PP) approaches. Results Forty-nine patients were included in the mITT analysis (mean age = 51.8 ± 6.4; 55% males). Metformin treatment was associated with a significant decrease in HOMA-IR. There was a significantly different mean change in e’ velocity during the study period between trial arms, both in the mITT (at 24 months, change of +0.67 ± 1.90 cm/s in metformin arm vs. −0.33 ± 1.50 cm/s in control arm) and PP populations (+0.80 ± 1.99 cm/s in metformin arm vs. −0.37 ± 1.52 cm/s in control arm), using a random intercept linear mixed model. There were no significant differences in peak oxygen uptake and SF-36 scores between trial arms. Conclusions Treatment with metformin of non-diabetic MetS patients with diastolic dysfunction, on top of lifestyle counseling, is associated with improved diastolic function.Keywords
Funding Information
- Merck KGaA
This publication has 33 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Standards of Medical Care in Diabetes—2012Diabetes Care, 2011
- Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Metformin attenuates ventricular hypertrophy by activating the AMP‐activated protein kinase–endothelial nitric oxide synthase pathway in ratsClinical and Experimental Pharmacology and Physiology, 2010
- Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1–Smad3 signalling pathwayCardiovascular Research, 2010
- Acute neurohumoral modulation of diastolic functionPeptides, 2009
- Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular massEuropean Heart Journal, 2006
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care, 2000